核苷(酸)类似物联合聚乙二醇干扰素治疗慢性乙型肝炎的临床疗效分析

Clinical efficacy analysis of nucleoside(acid)analogues combined with polyethylene glycol interferon in the treatment of chronic hepatitis B

目的观察聚乙二醇干扰素α-2b联合核苷(酸)类似物治疗慢性乙型肝炎的临床疗效。方法纳入淮安八二医院2017年1月至2022年6月慢性乙型肝炎患者,310例采用聚乙二醇干扰素α-2b联合核苷(酸)类似物治疗,作为观察组;仅采取核苷(酸)类似物治疗的310例患者作为对照组。观察两组的HBsAg转换率、HBV DNA转阴率以及肝功能复常率。结果观察组HBV DNA转阴率、ALT复常率、HBsAg转换率分别为301例(97%)、278例(89.7%)、120例(38.7%);对照组分别为288例(92.9%)、243例(78.3%)、8例(2.58%),差异均有统计学意义(χ^(2)=262.091、161.895、167.293,均P<0.01)。结论聚乙二醇干扰素α-2b联合核苷(酸)类似物治疗慢性乙型肝炎疗效显著。

Objective To study the clinical cure effect of polyethylene glycol interferonα-2b in combination with nucleotide(acid)analog in the treatment of chronic hepatitis B.Methods Three hundred and ten patients with chronic hepatitis B enrolled during January 1,2017 to June 30,2022 were given polyethylene glycol interferonα-2b plus nucleoside(acid)analogue and set as the observation group.Another 310 patients previously treated with nucleotide(acid)analogue were taken as the control group.The HBsAg conversion rate,HBV DNA conversion rate and liver function regaining rate in both groups were compared.Results HBV DNA conversion,liver function regaining rate and HBsAg conversion rate in the observation group were 301(97%),278(89.7%),120(38.7%),respectively,which were statistically significant different with those of 288(92.98%),243(78.3%),8(2.58%)in the control group(χ^(2)=262.091/161.895/167.293,all P<0.01).Conclusion The combination of polyethylene glycol interferonα-2b and nucleoside(acid)analogue is very effective in reducing the level of hepatitis B virus,and promoting liver function normalization in the treatment of chronic hepatitis B.